Skip to main content

Table 2 IC50 average parameters in nM for wild type (I356) and mutant (356T) P. falciparum isolates from West Africa and Central Africa for piperaquine (PPQ), quinine (QN), mefloquine (MQ), chloroquine (CQ), lumefantrine (LMF), desethylamodiaquine (DQ), pyronaridine (PND), dihydroartemisinin (DHA) and artesunate (AS)

From: Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates

Drugs

West Africa

Central Africa

Wild type I356

Mutant 356T

p value

Wild type I356

Mutant 356T

p value

Median (no)

Min-Max

Median (no)

Min-Max

Median (no)

Min–Max

Median (no)

Min–Max

PPQ

22.2 (49)

6.8–76.3

19.9 (66)

1.2–544

0.32

24.5 (36)

4.1–79

21.4 (70)

0.67–96.3

0.4

QN

69.1 (49)

11.7–906.3

162.6 (68)

6.2–590.5

0.001

98.2 (36)

17.6–365.2

183.4 (73)

28.9–538.4

0.02

MQ

30.4 (49)

2.9–89.8

22.4 (67)

0.8–100.6

0.01

33.3 (38)

0.7–97.9

21.5 (72)

0.62–133.9

0.04

CQ

37.4 (49)

6.2–283.2

26.5 (68)

5.5–359.5

0.1

42.8 (39)

4.1–474.2

26.9 (73)

5.79–325

0.01

LMF

3.0 (49)

0.5–61.54

4.0 (68)

0.6–18.2

0.6

2.8 (40)

0.6–15.5

3.6 (73)

0.55–22.4

0.5

DQ

19.2 (49)

3.4–169.2

27.1 (68)

2.5–185.1

0.07

22.8 (40)

5.1–152.8

20.8 (73)

4.7–152.9

0.4

PND

8.8 (48)

1.2–50.1

14.5 (66)

0.7–119.3

0.005

11.1 (38)

3.9–41

12.3 (67)

0.2–47.9

0.8

DHA

2.9 (49)

0.4–8.3

3.1 (68)

0.2–12.8

0.9

3.5 (40)

0.7–7.7

2.1 (73)

0.47–11.1

0.08

AS

1.8 (49)

0.4–15.48

1.8 (67)

0.2–9.8

0.6

2.5 (39

0.6–5.7

1.7 (71)

0.29–30.2

0.05

  1. West Africa: Benin, Burkina Faso, the Gambia, Ghana, Guinea, Ivory Coast, Niger, Mali, Nigeria and Togo
  2. Central Africa: Cameroon, Central African Republic, Chad, Gabon and Republic of Congo
  3. Italic p values refers to significant difference (p < 0.05)